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Low and middle income countries are faced with a range of challenges related to providing efﬁcient and
affordable health care. With non-communicable diseases (NCD) on the rise, there is a growing need to be
able to estimate resource requirements, costs and expected impact associated with various investment
strategies related to prevention and control of NCD. In this article, recently developed costing and health
impact models for non-communicable disease are reviewed, with a view to drawing out their main ﬁnd-
ings as well as methodological limitations. A key shortcoming is that earlier modelling efforts have taken
a vertical approach to costing, when in reality a more integrated, horizontal approach is needed in order
to effectively plan for scaled-up investment and system development. We subsequently describe how
the integration of an NCD module into the joint United Nations OneHealth tool will enable low- and
middle-income countries to bring NCD into an integrated process for national strategic health planning.TH E N E ED TO S T R ENG TH EN HEA L TH
F I NANC I NG
Low- and middle-income countries (LMIC) are
grappling with a range of challenges related to pro-
viding efficient and affordable health care. With
changing epidemiology and population structures,
noncommunicable diseases (NCD) are on the rise.
At the same time, only 19 of 68 countries with
the highest burden of child and maternal mortality
are on track to reach Millennium Development
Goal (MDG) 4 to reduce child mortality, and
at current rates of progress, few of these countries
will reach MDG5 to reduce maternal mortality
[1].
In order to move toward universal coverage,
countries must raise sufficient funds, reduce theand D. Chisholm are staff members of the World Health Organ
, and they do not necessarily represent the decisions, policy, or vi
Department of Health Systems Financing, World Health Organiz
rld Health Organization, Geneva, Switzerland. Correspondence:use of direct payments to finance services, and
improve efficiency and equity of health service
delivery [2]. Current health expenditure levels in
many low-income countries are not sufficient to at-
tain the standards of health increasingly expected by
the population. A recent analysis carried out for the
high-level Taskforce on Innovative International
Financing for Health Systems estimated that 49
low-income countries would on average (un-
weighted) need to spend about US$60 per capita
by 2015 to reach populations with a basic package
of health services [3]––a significant increase from
current levels of health spending––on average
US$32 per capita. This estimate included medicine
costs for some chronic diseases (such as cardiovas-
cular disease [CVD], diabetes, chronic obstructive
pulmonary disease, and asthma) but did not includeization. The authors alone are responsible for the views expressed in this
ews of the World Health Organization.
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with NCD.E S T IMAT I NG R E SOURC E N E ED S FOR
NCD : R E C ENT D EV E LOPMENT S
In parallel with the countdown to the 2015 MDG
targets, recent years have seen growing awareness
and concern about the escalating burden of NCD
and injuries worldwide not just from the public
health perspective but also from the economic
viewpoint. Lives lost to diseases such as cancer,
CVD, and diabetes––together with the often
long-standing disability associated with them––
have a direct economic impact on households and
communities, both through the uptake of health
services and goods (which diverts expenditure away
from other possible uses) and through reduced lev-
els of income or labor productivity. At the macro-
economic level, a recent study by the World
Economic Forum and the Harvard School of Pub-
lic Health estimated that cumulative losses in the
national product of LMIC over the period 2011–
2025 would amount to more than US$7 trillion
dollars if a concerted international response to this
burden were not mounted [4]. The recent High-
Level Meeting on Non-Communicable Diseases
and subsequent Political Declaration [5] provide
governments and other stakeholders with a clear
mandate for enhanced action and investment.
A key issue for debate––both for delegates at the
High-Level Meeting and for subsequent rollout by
countries––concerns the policies and strategies that
could or should form the backbone of a renewed
commitment to address NCD. There is growing
evidence for and consensus about the specific inter-
vention strategies that can effectively tackle leadingTable 1. Core set of NCD best buy interventions
Risk factor/disease Best buy interventions
Tobacco use Tax increases; smoke-free indoo
bans on tobacco advertising, pro
Harmful alcohol use Tax increases, restricted access t
Unhealthy diet and physical
inactivity
Reduced salt intake in food, rep
about diet and physical activity
CVD and diabetes Counseling and multidrug thera
with medium-high risk of develo
CVD), treatment of heart attacks
Cancer Hepatitis B immunization to pre
lesions to prevent cervical cance
Reprinted, with permission, from WHO [21].
CVD, cardiovascular disease.causes of NCD and their underlying risk factors
[6,7]. These interventions include population-level
measures (especially strategies to reduce consump-
tion of tobacco, alcohol, and salt, including im-
proved awareness of healthy lifestyles, increased
excise and tobacco taxes, and enhanced regulation)
and individual-level treatment and prevention
(such as the prevention of heart disease and stroke
or the early detection and treatment of cancer).
Several criteria influence the selection of such
global or national priorities for NCD prevention
and control, including the current and projected
burden of disease; the cost-effectiveness, fairness,
and feasibility of implementing interventions; and
political considerations. In particular, cost-effec-
tiveness information can help to identify which
interventions offer the greatest value for the money;
such evidence has now been assembled at the inter-
national level for all key contributors to––or risk
factors for––NCD [8–13].
In addition to evidence on the effectiveness and
cost-effectiveness of different policy or treatment
options, information is also needed on the feasibil-
ity and acceptability of interventions, including
their financial feasibility or affordability. In prepa-
ration for the UN High-Level Meeting on NCD,
the World Health Organization (WHO) identified
a core set of evidence-based ‘‘best buy’’ interven-
tions that met these criteria [6,14]. A best buy is
a concept that extends beyond economic efficiency
or cost-effectiveness. It is an intervention for which
there is compelling evidence that it is not only
highly cost-effective but is also feasible, low-cost,
and appropriate to implement within the con-
straints of the local health system. Table 1 summa-
rizes these best buys. Interventions that do not
meet all of these criteria––but which offer good va-
lue and have other attributes that recommend theirr workplaces and public places; health information and warnings;
motion and sponsorship
o retailed alcohol, bans on alcohol advertising
lacement of trans fat with polyunsaturated fat, public awareness
(via mass media)
py (including blood sugar control for diabetes mellitus) for people
ping heart attacks and strokes (including those with established
(myocardial infarction) with aspirin
vent liver cancer, screening and treatment of pre-cancerous
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Figure 1. Costs of scaling up chronic disease prevention strategies in 23 developing countries. Adapted, with permission, from Asaria
et al. [15] and Lim et al. [16].
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makers can consider best buys as a core set of inter-
ventions for priority scale-up and good buys as an
expanded set of interventions to be made available
when resources allow.
Once a set of best buys has been identified, the
question arises as to the financial resources that
would be required to implement them. A chronic
disease series published in 2007 by Lancet focused
on a subset of these priority interventions, includ-
ing price and nonprice demand reduction strategies
for tobacco use, salt reduction strategies, and com-
bination drug therapy for individuals at an elevated
risk of experiencing a CVD event [15,16]. Esti-
mates generated through this work indicated that
in 23 large developing economies (which account
for 80% of the burden of chronic disease in
LMIC), an estimated 32 million deaths could be
averted over 10 years due to these interventions
alone, at a cost of US$6 billion per year. As re-
ported in Figure 1, the average annual investment
needed ranges from well below US$1 to more than
US$3 per capita (with most of that expenditure
going on individual-based drug therapy for persons
with more than a 15% risk of experiencing a CVD
event over the next 10 years). Country-specific
costs inevitably vary considerably, depending on
the disease prevalence or risk factor exposure, cur-
rent and future demographic composition, as wellas the unit costs associated with different elements
of a health intervention (such as salaries, healthcare
visits, and diagnostic tests).
In addition to 32 million deaths averted from
2006 to 2015 in these 23 large developing countries
[15,16], losses in economic output would also be
reduced by US$8 billion over the same period [17].
The main drawbacks of this earlier analysis were
that it was restricted to a very limited number of
interventions and countries, meaning that no com-
plete estimate was available for ascertaining the ex-
pected costs of scaling-up a broader set of effective
population-based and individual healthcare inter-
ventions for NCD and their major risk factors.
This information gap was seen as a serious imped-
iment to appropriate resource mobilization and
financial planning at the global and national levels.
In response to this information gap, WHO has
developed a financial planning tool for scaled-up
delivery of a defined set of chronic disease inter-
vention strategies. It is a tool for medium-term
planning that can be used to provide forecasts of
financial resource needs at the global, national, or
subnational levels and is based on methods used
to derive global ‘‘price tags’’ for scaling up interven-
tions related to attainment of the MDG, including
human immunodeficiency virus/acquired immuno-
deficiency syndrome, tuberculosis, malaria, and
child health.
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Figure 2. Global price tag for scaling up NCD best buys in LMIC. Reprinted, with permission, from WHO [21].
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source needs at the international level, the WHO
NCD costing tool was used to generate a global
price tag for scaled-up delivery of NCD best buys
in LMIC [14]. Key data sources for this costing
exercise included UN Population Division statis-
tics, global burden of disease and risk-factor sur-
veillance estimates, international treatment
guidelines, and WHO cost databases. The period
of scaling-up was set as 2011–2025, by which time
desired levels of treatment coverage (80% in the
base case) were assumed to be reached. Full imple-
mentation of population-based strategies is ex-
pected to occur more rapidly (after approximately
5–6 years). Analysis was performed for 42 LMIC
(with populations in excess of 20 million), which
between them account for 90% of the NCD burden
in developing regions of the world (and 77% of the
global NCD burden).
The total cost of implementing the full set of
best buy interventions across all LMIC over the
period 2011–2025 is estimated to be US$170 bil-
lion, at an average of US$11.4 billion per year
(Fig. 2); population-based measures that address
tobacco and harmful alcohol use, as well as un-
healthy diet and physical inactivity, account for a
very small fraction of the total price tag (US$2 bil-
lion per year––less than US$0.40 per person). Ex-
pressed in per capita terms, these costs amount to
an annual investment of under US$1 in low-in-
come countries, US$1.50 in lower-middle-income,
and US$3 in upper-middle-income countries.
These values are largely commensurate with the
earlier estimates shown in Figure 1, even though
a number of additional measures are included in
this global price tag analysis. A key reason behindthat finding is the much higher threshold value
used for providing multidrug therapy for those at
an elevated CVD risk (30% vs. 15%); in addition,
the resource needs associated with certain program
elements of tobacco control were revised downward
following in-depth consultation and resource
profiling.
The primary use of the WHO NCD costing
tool is ultimately directed at the national level.
The tool has been developed in Microsoft Excel
(Redmond, Washington) and is designed to be
used by country investigators responsible for
NCD program planning or development. Key ana-
lytical steps required by national users include: def-
inition of the intervention package; estimation of
current versus target levels of need and coverage
in the population; and calculation of year-on-year
resource costs required over a specified period to
reach desired coverage. The tool generates esti-
mates of total and incremental costs of scaled-up
provision, broken down by category of intervention
(e.g., population-wide interventions versus individ-
ual healthcare interventions), cost category (e.g.,
human resources, physical capital), activity (e.g.,
regulation versus individual treatment), and time
(e.g., costs at different levels of policy formulation).
To optimize the flexibility and usefulness of the
WHO NCD costing tool at the national level, the
set of interventions from which policy makers and
planners can choose may need to go beyond the ini-
tial subset of best buys identified by WHO (e.g.,
tobacco cessation, brief advice for heavy drinkers,
early detection of breast cancer). Accordingly, re-
source-need profiles and cost estimates for other
interventions have been integrated into the tool
to give countries a better sense of the resource
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M a r c h 2 0 1 2 : 5 3 – 6 0
Stenberg and Chisholm 57
Assessing Resource Needs for NCDimplications associated with the delivery of a more
comprehensive public health response to NCD. It
should be noted, however, that the purpose of
the tool is to aid financial planning for scaling up
interventions that have been prioritized; it is not
a cost-effectiveness or priority-setting tool.
Although useful and usable as an instrument for
evidence-based national planning in the area of
NCD control and prevention, the currently avail-
able WHO NCD costing tool is limited in a num-
ber of key respects:
 The tool is restricted to a discrete number of diseases
and risk factors, meaning that other NCD conditions
accounting for a significant portion of the global bur-
den of disease––such as other renal and liver diseases,
gastrointestinal diseases, neurological diseases (other
than stroke) and mental disorders––have been
excluded.
 The tool does not provide estimates of the health
impacts associated with the combined implementa-
tion of the best buy strategies, in particular the num-
ber of premature deaths avoided as interventions are
scaled-up. This information gap represents a key
piece of analysis that would need to be undertaken
to demonstrate the return on the large-scale invest-
ments indicated. Related to this point, cost estimates
do not take into account the impact of preventive
measures on subsequent disease rates, such as the
impact of tobacco control measures on future rates
of ischemic heart disease or stroke; rather, disease
rates have been assumed to be constant throughout
the scale-up period. As a consequence, estimated
costs of scale-up might be expected to be overesti-
mated (however, it is also the case that in countries
with positive population growth and/or increased life
expectancy, more people will be exposed to NCD risk
factors, thus mitigating the extent of overestimation).
 The tool does not take into account the costs of over-
coming system-wide constraints, such as an inability
to train and retain health professionals.A HEA L TH S Y S T EMS AP P ROACH : TH E
ONEH EA L TH TOOL
Even though it is important to undertake program-
specific analysis, as described for NCD, LMIC
need to take into account the full disease burden
and health system in order to set priorities for
the national health sector. Recent years have seen
a plethora of tools developed to assist national
planning for specific diseases or programs [18].
The re-emergence of vertical program planning
has been reinforced by some of the global healthinitiatives, where evidence indicates that disease-
specific and health program-specific funding has
undermined governments’ abilities to build na-
tional health systems [19]. Although many coun-
tries have seen substantial increases in external
development assistance for health in recent years,
they may lack the capacity and bargaining power
to effectively channel these toward national priori-
ties [19,20].
Poor health outcomes in low-income countries
can be explained by underinvestment in health sys-
tems. It is essential to ensure that systems are
strengthened to take on not just the MDG, but
also the growing burden of NCD. The average
number of physician, midwifery, and nursing per-
sonnel in low-income countries is 9.5 per 10,000
[21], compared with an estimated critical mini-
mum threshold of 22.8 per 10,000 [22]. The anal-
ysis carried out for the high-level Taskforce on
Innovative International Financing for Health Sys-
tems estimated that out of the additional resources
estimated to be required, 74% represent invest-
ments in the health system [3]. Still, only a small
share of current official development assistance
for health is estimated to go toward health systems
[23].
To summarize, progress toward universal cover-
age is suffering from underinvestments in the
health system, coupled with disease-specific initia-
tives that too seldom take an integrated approach
to planning for population health. Unfortunately,
what is seen today in many countries are delinked
planning cycles for individual programs, which
are not synchronized across the health sector, as
can be seen by an examination of the WHO Coun-
try Planning Cycle Database [24].
To combat these challenges and facilitate sys-
tems-focused national planning, the UN Inter-
Agency Working Group on Costing, established
in 2008, has taken on the task to strengthen coun-
try analysis of health-sector requirements and their
related costs, through the development of an inte-
grated planning model––the OneHealth tool [25].
The OneHealth tool aims to support integrated
planning processes in countries, by bringing together
disease-specific program and health systems plan-
ning. The tool was born out of a review of existing
tools for strategic planning and costing, which found
that existing tools did not adequately allow for sec-
tor-wide scenario analysis [18]. TheOneHealth tool
to date includes detailed planning modules for pro-
grams related to the MDG, such as nutrition, child
health, and malaria, as well as modules for health
Figure 3. The modular structure of OneHealth.
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infrastructure) (Fig. 3). It aims to facilitate planning
that incorporates health promotion, prevention,
treatment, and disease management.
The objective is to ensure that the development
of national health plans is carried out within a
framework of health system capacity assessment,
taking into account financial sustainability and out-
comes-based planning. As such, OneHealth incor-
porates modules for conducting a financial space
assessment to look at fiscal sustainability, as well
as modules for estimating the predicted health im-
pact of scaling up interventions over time (mortal-
ity and morbidity). The tool incorporates pre-
existing UN epidemiological reference group mod-
els, such as the Lives Saved Tool [26], the AIDS
Impact model for human immunodeficiency virus/
acquired immunodeficiency syndrome interven-
tions [27–29], and the FamPlan model, which
computes the relationship between family planning
and total fertility rate [30,31].
The key strength of OneHealth is its ability to
pull different programmatic areas together and to
enable a consolidated analysis across health sys-tems, health impact, and financial space. These
three areas need to be considered jointly for the
entire health sector. Looking at these areas for
just one program brings limited added value. For
example, the health impact achieved by scaling
up breast-feeding promotion for child health can
have a substantial impact on future NCD burden.
The scale-up of immunization against human
papillomavirus can similarly reduce the need for
screening and treating women with cervical can-
cer. The analysis of benefits across national pro-
grams and over time is highly beneficial to
inform priority setting.
At the same time, realistic planning needs to
take into account health system capacity. Scaling
up services by a factor of 50% or even by 10% over
the next 5–10 years may require substantial invest-
ments in the medicines supply chain, in health
worker availability and deployment, and in the
establishment of management and supervisory pro-
cesses. The purpose of OneHealth is to provide na-
tional planners with a tool that enables them to
make an informed analysis and to set realistic tar-
gets for the medium term (3–10 years).
 An assessment of the health system implications of
the planned scale-up and the related resource
costs, such as translating the number of required
outpatient visits into numbers of full-time health
workers.
 Facilitated integration of program- or disease-spe-
cific plans into broader national health plans.
 Ensuring the use of consistent approaches for
planning and costing for NCD, across national
programs, UN agencies, and partners.
 Modeling the predicted health impact of scaling
up NCD interventions, within an overall envelope
of health service scale-up.
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MODUL E FOR ONEH EA L TH
The first version of OneHealth, released in early
2012, does not yet include planning modules for
NCD prevention and control. Therefore, the next
step is to incorporate NCD into the tool, drawing
on current developments in modeling resource
requirements and expected impacts of NCD-re-
lated strategies.
Whereas NCD is not one of the MDG, it is
increasingly being raised as a priority at the country
level. Ministry of Health counterparts who have
been exposed to OneHealth to date have expressed
high satisfaction with the capability of the tool to
support integrated planning, but they have also
underlined the need to incorporate planning for
NCD into the tool. Ongoing work to ensure that
future versions of OneHealth include modules for
planning and costing for chronic diseases will allow
LMIC to bring NCD into an integrated process
for national strategic health planning.
As part of the development of a NCD module
within OneHealth, special attention will need to
be given to modeling of composite as well as
disaggregated health gains brought about by
interventions. Such an analysis of health impacts
provides the information required to assess the
sizeable returns on investment generated through
the scale-up of prioritized NCD control and pre-
vention strategies. Illustrating these positive im-
pacts is in line with the overall objectives of
OneHealth, which is to demonstrate the costs
and potential impact associated with different
investment scenarios.
The added value of including an NCD compo-
nent into OneHealth includes: Costing of priority health interventions for NCD,
including population-based strategies as well as
clinical interventions. OneHealth comes equipped
with defaults for standard treatment protocols that
the country-level user can adjust as needed to
adapt to the national context.CONC LU S I ON S
LMIC are faced with a range of challenges related
to providing efficient and affordable health care.
With NCD on the rise, there is a growing need
for Ministries of Health to be able to estimate re-
source requirements, costs, and expected impact
associated with various investment strategies re-
lated to prevention and control of NCD. Several
models have been developed to date to allow for
costing and assessing health benefits of NCD
interventions, but have not been brought together
with an analysis of other programs and diseases.
The integration of an NCD module into the joint
UN OneHealth tool will allow LMIC to bring
NCD into an integrated process for national stra-
tegic health planning.ACKNOWLEDGMENT S
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